Millennium reports 5.2% stake in Forte Biosciences

Rhea-AI Filing Summary

Forte Biosciences (Common Stock): A joint Schedule 13G filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,062,182 shares, representing 5.2% of the class, with the cover date 06/04/2026. The filing explains these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. The filers executed a Joint Filing Agreement dated June 5, 2026 and provided the issuer address at 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247.

Insights

Institutional Ownership Analyst

Millennium reports a passive 5.2% stake via shared control of 1,062,182 shares.

The filing lists shared voting and shared dispositive power over 1,062,182 shares (5.2% of the class) as of 06/04/2026. It attributes holdings to entities under Millennium's voting and investment discretion rather than direct sole ownership.

Governance implications hinge on whether this group coordinates future filings or transactions; subsequent SEC schedules or press releases would disclose any change in status or voting intentions.

Key Figures

Reported shares with shared power: 1,062,182 shares Percent of class: 5.2% CUSIP: 34962G208 +2 more

5 metrics

Reported shares with shared power 1,062,182 shares shared voting and dispositive power reported on cover page dated 06/04/2026

Percent of class 5.2% percent of class shown on the cover page

CUSIP 34962G208 Common Stock, par value $0.001 per share

Issuer address 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247 Item 1(b) issuer principal executive office

Joint Filing Agreement date June 5, 2026 Exhibit I: Joint Filing Agreement among the filers

Key Terms

Schedule 13G, shared dispositive power, Joint Filing Agreement

3 terms

Schedule 13G regulatory

"Item 2(a) Name of person filing: Millennium Management LLC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

shared dispositive power regulatory

"Shared Dispositive Power 1,062,182.00"

Joint Filing Agreement legal

"Exhibit I: Joint Filing Agreement, dated as of June 5, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Forte Biosciences (FBRX)?

The filers report shared voting and dispositive power over 1,062,182 shares, representing 5.2% of the class as shown on the cover page dated 06/04/2026. The shares are held by entities under Millennium's control.

Who signed the Schedule 13G for FBRX?

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are named filers; signatures include Gil Raviv (Global General Counsel) and Israel A. Englander, dated 06/05/2026.

Does the filing state sole ownership or shared control?

The filing specifies shared voting power and shared dispositive power of 1,062,182 shares. It lists zero sole voting and dispositive power for the named filers and describes holdings as controlled through affiliated entities.

Is there an agreement among the filers?

Yes. Exhibit I is a Joint Filing Agreement dated June 5, 2026 among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, executed in connection with the Schedule 13G filing.

What address is listed for the issuer in the filing?

The issuer's principal executive office is listed as 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247 in Item 1(b) of the Schedule 13G cover page.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 05:17 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

34962G208

(CUSIP Number)

06/04/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,062,182.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,062,182.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,062,182.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,062,182.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,062,182.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,062,182.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,062,182.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,062,182.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,062,182.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/05/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/05/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	06/05/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of June 5, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.